GOLDEN, Colo., January 17, 2023 /PRNewswire/ — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”)a precision oncology company with extensive protein and phosphoprotein testing for breast cancer, today announced that it is supporting George Mason University participating in the White House Cancer Moonshot Initiative.
Mick Ruxin, MD, Chief Executive Officer of Theralink said, “We are very excited to learn that Reverse Phase Protein Assay (RPPA) technology will be used in the Cancer Moonshot Initiative.” Previously, Theralink acquired a commercial license for the RPPA technology through an agreement with George Mason University. He added, “Theralink looks forward to helping George Mason University and the Center for Applied Proteomics and Molecular Medicine in any way we can is a very important way to treat cancer. “
Recently, George Mason University announced that Mason scientists will participate in the White House Cancer Moonshot Initiative, and their work will contribute to the work of reducing the number of cancers. The US government is collaborating with researchers to reduce cancer deaths by bringing together a large group of patients, advocates, researchers, and clinicians.
Researchers from Mason’s Center for Applied Proteomics and Molecular Medicine (CAPMM) in George Mason University The College of Science is working on molecular technology that can better identify the most effective drugs against specific cancers.
“I think it is very realistic to reduce the number of cancer deaths in half in 25 years,” said Emanuel “Chip” Petricoin, University Professor and co-founder and director of CAPMM. Petricoin is also the Chairman of Theralink’s Scientific Advisory Board – whose mission is to bring this novel, groundbreaking molecular technology to cancer patients across the US and to assist oncologists in choosing a biologically based treatment for each patient.
Dr. Ruxin and Petricoin are bringing together the most passionate people in the fight against cancer. They are encouraging collaboration to fight this disease with the goal of reducing morbidity and mortality for all cancer patients. “We are working together to complete the investigation George Mason University and commercial efforts at Theralink Technologies to help improve multi-cancer care for all patients and their families and friends,” said Dr. Ruxin.
Company opinion Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, precision medicine company with a CLIA-accredited and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s technology addresses multiple areas of oncology and drug development. In addition to the company’s first trial in advanced breast cancer, Theralink is working hard on a second trial that is planned to be pan-tumor for solid tumors in several types of tumors such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal. , lungs, prostate, etc. Theralink provides accurate oncology information through its powerful Theralink® Reverse Phase Protein Array test to help biopharmaceutical companies and medical professionals identify responders and non-responders to FDA-approved drugs and researchers. Theralink aims to help improve cancer outcomes for patients, help uncover therapeutic strategies for oncologists, and support the development of biopharmaceuticals by using a genomics approach to molecular profiling that directly measures drug levels and activity. For more information, please visit www.theralink.com.
Forward-Looking Comments
Certain words in this article are “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything related to future financial results, patient enrollment and future development plans. , and thus expected. Forward-looking statements involve risks and uncertainties that cannot be predicted or quantified based on our expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties described from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based these forward-looking statements primarily on our expectations and expectations for future years and how the economy will affect our business, and although the company believes that the expectations expressed in such forward-looking statements are reasonable, it cannot endorse them. to ensure that such expectations will be correct. Accordingly, future events and actual results may differ materially from those expressed, implied, or implied by the forward-looking statements contained herein. The company is under no obligation to issue any public statements reflecting events or developments after this date.
Theralink Technologies Company Profile
